How DUPIXENT May Help

Debbie

DUPIXENT MyWay® Patient Ambassador,
on DUPIXENT
Individual results may vary.
"I had learned over the years that if I didn't advocate for myself, no one would... It was clear to me that I needed to explore additional treatment options."

Get Down to the Details

DUPIXENT was studied in 3 clinical trials with more than 2,100 adults with uncontrolled moderate-to-severe eczema (atopic dermatitis).


What you should know about the patients in these studies:

52%
had moderate atopic dermatitis
48%
had severe atopic dermatitis
Average age
≈ 38 years
Average duration of the disease
≈ 28 years
Average body surface area involvement
≈ 55%

In two 16-week clinical trials with DUPIXENT when used alone compared to a placebo:

Nearly half of patients saw 75% skin improvement and some even saw 90% improvement.
Almost 4 times more patients taking DUPIXENT saw clear or almost clear skin as compared with those not taking DUPIXENT (37% taking DUPIXENT as compared to 10% taking placebo)
Patients experienced significant itch reduction, some patients as early as 2 weeks

The most common side effects include injection site reactions, pain in the throat (oropharyngeal pain) and cold sores in your mouth or on your lips. Eye and eyelid inflammation, including redness, swelling and itching have been seen in patients who have atopic dermatitis.

See the Change

Results when DUPIXENT was used alone†‡ every other week for 16 weeks compared to patients taking placebo.

DUPIXENT Not taking DUPIXENT (taking placebo)
37% of patients had clear or almost clear skin compared to 10% taking placebo
47% of patients showed a 75% improvement in their skin compared to 13% taking placebo
33% of patients showed a 90% improvement in their skin compared to 7% taking placebo

Results from “DUPIXENT alone” derived from averaging results from 2 studies

All patients used a daily moisturizer

Results when DUPIXENT was used every other week for 16 weeks with topical corticosteroids compared to patients taking topical corticosteroids.

DUPIXENT + topical corticosteroids Not taking DUPIXENT (taking placebo + topical corticosteroids)
39% of patients had clear or almost clear skin when DUPIXENT was used with topical corticosteroids compared to 12% taking placebo with topical corticosteroids
69% of patients showed a 75% improvement in their skin when DUPIXENT was used with topical corticosteroids compared to 23% taking placebo with topical corticosteroids
40% of patients showed a 90% improvement in their skin when DUPIXENT was used with topical corticosteroids compared to 11% taking placebo with topical corticosteroids

Feel the Change

Patients experienced a significant itch reduction while participating in clinical trials.

DUPIXENT Not taking DUPIXENT (taking placebo) 
39% of patients had significant itch reduction at 16 weeks when DUPIXENT was used alone compared to 11% taking placebo
DUPIXENT + topical corticosteroids Not taking DUPIXENT (taking placebo + topical corticosteroids)
59% of patients had significant itch reduction at 16 weeks when DUPIXENT was used with topical corticosteroids compared to 20% taking placebo with topical corticosteroids

Results at 1 Year (DUPIXENT + Topical Corticosteroids)

DUPIXENT started working quickly and continued to show results, with the majority of patients seeing significant skin improvement and itch reduction at 1 year of treatment when used with topical corticosteroids.

These results show the percentage of patients who experienced the following results at 1 year (52 weeks) while taking DUPIXENT once every other week while using topical corticosteroids compared to patients taking placebo and topical corticosteroids.

DUPIXENT + topical corticosteroids Not taking DUPIXENT (taking placebo + topical corticosteroids)
36% of patients had clear or almost clear skin when DUPIXENT was used with topical corticosteroids compared to 13% taking placebo with topical corticosteroids
65% of patients saw a 75% improvement in their skin when DUPIXENT was used with topical corticosteroids compared to 22% taking placebo with topical corticosteroids
51% of patients had significant itch reduction at 1 year when DUPIXENT was used with topical corticosteroids compared to 13% taking placebo with topical corticosteroids

The safety profile of DUPIXENT and topical corticosteroids through Week 52 (trial 3) was generally consistent with the safety profile observed at Week 16.

Recommended Dosing Information

The initial dose of DUPIXENT is two injections (600 mg) under the skin at different injection sites. After that, it is taken as one 300 mg injection every other week at different injection sites. DUPIXENT can be used with or without topical corticosteroids.

Talk to your healthcare professional and download the detailed Instructions for Use for information on how to prepare and inject DUPIXENT and how to properly store and dispose used DUPIXENT Pre-Filled Syringes. Do not try to inject DUPIXENT until you have been shown the right way by your healthcare provider.

Find Out More
Connect With a Specialist Who Treats Eczema

Use this tool to easily find nearby specialists with experience in treating adults with uncontrolled moderate-to-severe eczema (atopic dermatitis).

Sanofi US and Regeneron do not endorse or recommend any particular physician, and search results do not include a comprehensive list of doctors in your area.